Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 203 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer April 14, 2021 New Mom Was Told a Lump in Her Breast Was “Built-Up... April 5, 2019 Cancer Research UK’s charity Christmas cards now available October 28, 2021 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS Colorectal Cancer Screening: The Silver Lining Patient Guide in Bladder Cancer Now Available Also in Italian Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... Disparities in Cancer Care Between Citizens and Refugees in Lebanon
